Literature DB >> 17172823

In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.

Jörg Reichrath1, Martin Rech, Maryam Moeini, Eckart Meese, Wolfgang Tilgen, Markus Seifert.   

Abstract

We studied effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], its analog seocalcitol (EB 1089), and 25-hydroxyvitamin D3 [25(OH)D3], on the growth of seven melanoma cell lines. While three cell lines (MeWo, SK-Mel-28, SM) responded to antiproliferative effects of active vitamin D analogs, the others (SK-Mel-5, SK-Mel-25, IGR, MeUuso) were resistant. A strong induction (7000-fold) of 1,25-dihydroxyvitamin D-24-hydroxylase (24OHase, CYP24) mRNA was detected in responsive cell lines along with 1,25(OH)2D3-treatment, indicating functional integrity of vitamin D receptor (VDR)-mediated transcription. In contrast, induction of 24OHase was much lower in resistant melanoma cells (70-fold). VDR mRNA was induced up to 3-fold both in responsive and resistant cell lines along with 1,25(OH)2D3-treatment. RNA for vitamin D-activating enzymes vitamin D-25-hydroxylase (25OHase, CYP27A1) and 25-hydroxyvitamin D-lalpha-hydroxylase (lalphaOHase, CYP27B1) was detected in all melanoma cell lines analyzed, additionally we show splicing variants of lalphaOHase in SK-Mel-28 cells. Expression of 250Hase and laOHase was marginally modulated along with treatment. Proliferation of melanoma cells was not inhibited by treatment with 25(OH)D3, indicating no significant stimulation of endogeneous production of antiproliferative acting 1,25(OH)2D3. In conclusion, we characterize the vitamin D endocrine system in melanoma cells and demonstrate that the majority of melanoma cell lines analyzed is resistant to antiproliferative effects of 1,25(OH)2D3. It can be speculated that these alterations are of importance for pathogenesis and growth of metastasizing malignant melanoma. Additionally, our findings indicate that only a minority of cases with metastasizing melanoma may represent a promising target for palliative treatment with new vitamin D analogs that exert little calcemic side effects or for pharmacological modulation of 1,25(OH)2D3-synthesis/metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17172823     DOI: 10.4161/cbt.6.1.3493

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  37 in total

Review 1.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

2.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

Review 3.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

Review 4.  Skin cancer and vitamin D: an update.

Authors:  Candy Wyatt; Rachel E Neale; Robyn M Lucas
Journal:  Melanoma Manag       Date:  2015-02-25

5.  Activation of vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines.

Authors:  Pit Sertznig; Markus Seifert; Wolfgang Tilgen; Jörg Reichrath
Journal:  Dermatoendocrinol       Date:  2009-07

6.  Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Andrzej T Slominski
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

Review 7.  Vitamin D in cutaneous carcinogenesis: part II.

Authors:  Jean Y Tang; Teresa Fu; Christopher Lau; Dennis H Oh; Daniel D Bikle; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

Review 8.  Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook.

Authors:  Jörg Reichrath; Christos C Zouboulis; Thomas Vogt; Michael F Holick
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 9.  Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.

Authors:  Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino
Journal:  J Nephrol       Date:  2016-04-09       Impact factor: 3.902

Review 10.  Cytochromes p450 and skin cancer: role of local endocrine pathways.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.